Trials / Approved For Marketing
Approved For MarketingNCT05164250
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- —
- Age
- —
- Healthy volunteers
- —
Summary
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
Detailed description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN5458 |
Timeline
- First posted
- 2021-12-20
- Last updated
- 2025-11-10
Source: ClinicalTrials.gov record NCT05164250. Inclusion in this directory is not an endorsement.